Therapeutic Phlebotomy Management for Hereditary Hemochromatosis

Induction Phase

• Weekly therapeutic phlebotomy of 500 mL is the first‑line treatment for hereditary hemochromatosis, with a target ferritin of 50–100 µg/L during induction and lifelong maintenance thereafter. 1
• Initiate weekly phlebotomy immediately in patients with confirmed hemochromatosis and elevated ferritin, removing 500 mL per session until ferritin reaches 50–100 µg/L. 2
• Check hemoglobin/hematocrit before each phlebotomy session to avoid excessive anemia. 1
• Reduce phlebotomy frequency if hemoglobin falls below 12 g/dL; pause treatment entirely if it falls below 11 g/dL. 3
• Limit hemoglobin decline to no more than 20 % from baseline during induction. 1
• Measure ferritin every 10–12 phlebotomies during the initial treatment period. 2
• Once ferritin reaches 200 µg/L, increase ferritin monitoring to every 1–2 treatment sessions. 3
• Discontinue weekly phlebotomy when ferritin has fallen to the 50–100 µg/L range. 3
• If baseline ferritin is < 1000 µg/L without liver enzyme elevation, proceed directly to phlebotomy without liver biopsy. 4
• For any ferritin level accompanied by end‑organ damage, initiate regular phlebotomy with the same ferritin targets. 4

Maintenance Phase

• Continue phlebotomy lifelong at individualized intervals (typically every 2–6 months) to keep ferritin between 50–100 µg/L. 1
• Check hemoglobin before each maintenance phlebotomy session. 3
• Monitor ferritin and transferrin saturation every 6 months. 3

Blood Donation Eligibility

• Blood removed during therapeutic phlebotomy may be used for transfusion in patients with uncomplicated hemochromatosis and no significant organ damage during the maintenance phase, as deemed safe by the American Red Cross and the U.S. Food and Drug Administration. 1

Dietary and Lifestyle Recommendations

• Avoid vitamin C supplements during active iron depletion because they accelerate iron mobilization and increase oxidative stress. 4
• Do not take iron supplements. 2
• Refrain from consuming raw or undercooked seafood due to the risk of Vibrio vulnificus infection. 4
• Prevent wound exposure to seawater. 3
• No specific dietary iron restriction is required; dietary changes remove only ~2–4 mg/day versus ~250 mg/week removed by phlebotomy. 1
• Limit daily red‑meat consumption. 3
• Avoid moderate to heavy alcohol intake; patients with advanced liver disease should abstain completely. 3

Alternative Therapies When Phlebotomy Is Contraindicated

Erythrocytapheresis

• Erythrocytapheresis is the preferred alternative when phlebotomy is not tolerated, providing fewer hemodynamic shifts and returning valuable blood components. 3
• The same ferritin targets apply: 50 µg/L for induction and 50–100 µg/L for maintenance. 3

Iron Chelation Therapy

• Use chelation only after a careful risk‑benefit assessment when neither phlebotomy nor erythrocytapheresis is feasible. 3
• Deferoxamine 20–40 mg/kg/day subcutaneously is the traditional regimen, administered as a continuous 8–12‑hour nightly infusion for 5–7 nights per week, achieving maximal urinary iron excretion of ≈2 g/24 h. [1] [2]
• Deferasirox is an oral alternative, but concerns about adverse events limit its use in hereditary hemochromatosis. 2
• Chelation is first‑line for secondary iron overload from ineffective erythropoiesis (e.g., thalassemia), not for hereditary hemochromatosis. 2

Safety Considerations

• In patients with cardiomyopathy or arrhythmias, rapid iron mobilization can precipitate sudden death; consider slower phlebotomy schedules or chelation instead. 1
• Monitor closely to avoid iron deficiency from excessive maintenance phlebotomy; deficiency may persist for months and cause significant symptoms. 3

Management of Hemochromatosis

Initial Assessment and Induction Phase

• Patients with confirmed hemochromatosis and iron overload should undergo weekly therapeutic phlebotomy (500 mL) until serum ferritin reaches 50-100 μg/L, then continue maintenance phlebotomy lifelong to keep ferritin in this target range, as recommended by the American Association for the Study of Liver Diseases 5
• Before initiating treatment, obtain baseline studies including serum ferritin level to quantify iron burden, liver function tests to assess hepatic involvement, complete blood count to ensure adequate hemoglobin for phlebotomy, and renal function to establish baseline, according to the American Association for the Study of Liver Diseases 5
• Remove 500 mL of blood weekly or biweekly as the patient tolerates, and check hemoglobin/hematocrit before each phlebotomy session to prevent excessive anemia, as recommended by the American Association for the Study of Liver Diseases 5, 6

Maintenance Phase and Dietary Modifications

• Continue phlebotomy at individualized intervals (typically every 2-4 months) to maintain ferritin between 50-100 μg/L, and monitor ferritin monthly initially, then adjust frequency based on stability, according to the American Association for the Study of Liver Diseases 5, 6
• Avoid vitamin C supplements entirely, especially during active iron depletion, as vitamin C accelerates iron mobilization and can increase oxidative stress, as recommended by the American Association for the Study of Liver Diseases 5, 6

Special Populations

• In patients with cardiomyopathy or arrhythmias, rapid iron mobilization increases risk of sudden death, and consider slower phlebotomy schedule or iron chelation, according to the American College of Cardiology 5
• Consider more relaxed ferritin targets during maintenance (up to 200 μg/L for women, 300 μg/L for men) in elderly patients, as recommended by the American Geriatrics Society 7

Alternative Treatment and Critical Monitoring Parameters

• Deferoxamine 20-40 mg/kg/day subcutaneously is the traditional chelation option for patients who cannot tolerate phlebotomy, according to the American Association for the Study of Liver Diseases 5, 6
• Monitor hemoglobin/hematocrit before each phlebotomy, serum ferritin every 10-12 phlebotomies during induction, then monthly during maintenance, and liver function tests periodically to assess for hepatic complications, as recommended by the American Association for the Study of Liver Diseases 5

Initiation and Management of Therapeutic Phlebotomy in Hereditary Hemochromatosis

Diagnostic Thresholds that Trigger Phlebotomy

• Initiate weekly therapeutic phlebotomy when transferrin saturation exceeds 45 %–55 % in adults with suspected hereditary hemochromatosis. (moderate‑quality evidence; case series) 8
• Begin phlebotomy in individuals with confirmed C282Y homozygosity or compound heterozygosity for HFE mutations, even if symptoms are absent. (moderate‑quality evidence; case series) 9

Clinical Scenarios Requiring Immediate Phlebotomy

• Asymptomatic C282Y homozygotes with serum ferritin < 1000 µg/L and normal liver enzymes should start phlebotomy without a prior liver biopsy; this preventive approach reduces progression to cirrhosis and diabetes. (moderate‑quality evidence; case series) 10
• When any end‑organ damage (e.g., liver disease, cardiomyopathy, diabetes, arthropathy, skin hyperpigmentation) is present, phlebotomy should be started regardless of ferritin level; initiating treatment before cirrhosis develops yields 10‑year survival comparable to age‑matched healthy controls. (moderate‑quality evidence; case series) 9
• In patients with established cirrhosis, phlebotomy can still be beneficial, producing histologic improvement in 13 %–50 % of cases, with the greatest effect in early‑stage fibrosis. (moderate‑quality evidence; case series) 10

Timing of Treatment Initiation

• Do not postpone phlebotomy while awaiting genetic confirmation if phenotypic tests (elevated ferritin and transferrin saturation) already indicate iron overload; early intervention prevents irreversible organ injury. (moderate‑quality evidence; case series) 8

Evidence Quality and Consensus

• Multiple case‑series demonstrate that initiating phlebotomy before cirrhosis normalizes long‑term survival compared with untreated patients; this evidence underpins the current standard of care despite the lack of randomized trials. (moderate‑quality evidence; case series) 9
• Hepatology experts consider therapeutic phlebotomy the accepted standard of care for hereditary hemochromatosis, even though Level 1 (randomized) evidence is absent. (expert consensus; moderate‑quality) 8